Serbian lymphoma study group: demografic characteristics of 257 patients with follicular lymphoma

Olivera Simonović; Lana Mačukanović - Golubović; Boško Andjelić; Darko Antić; Biljana Mihaljević

doi:10.2298/5342

Olivera Simonović Clinic for hematology and clinical immunology, Clinical Center Niš
Lana Mačukanović - Golubović Clinic for Hematology and Clinical Immunology, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
Boško Andjelić Clinical Center of Serbia, Belgrade, Serbia
Darko Antić Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Biljana Mihaljević Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/5342

Keywords: lymphoma, follicular, serbia, predictive value of tests, combined modality therapy,

Abstract

Background/Aim. Follicular lymphoma (FL) is a B-cell tumor usually with indolent clinical course, yet in some cases the course of the disease can be very aggressive. The aim of the research was to determine distribution of patients into prognostic groups based on the International Prognostic Index (IPI) and Folicular Lymphoma International Prognostic Index (FLIPI) criteria, as well as to determine the importance of classifying patients into the prognostic groups, since this could potentially have the influence on selection of the treatment modality. Methods. The retrospective study was performed on 257 patients with follicular lymphoma diagnosed between January 2000 and April 2011. Results. Based on the IPI score, 153 (59.53%) patients had low risk, 57 (22.18%) low intermediate risk, 15 (5.84%) high intermediate risk, 9 (3.50%) high risk, whereas the classification of 23 patients diagnosed with FL remained with unknown risk according to the IPI. Based on the FLIPI prognostic index, 113 (43.97%) patients had low risk, 70 (27.24%) intermediate risk and 51 (19.84%) high risk, whereas the classification of 23 (8.95%) patients remained unknown. On the basis of the FLIPI 2 prognostic index, 48 (18.68%) patients had low risk, 145 (56.42%) intermediate risk and 41 (15.95%) high risk. The classification into prognostic groups for 23 (8.95%) patients remained unknown. According to the IPI, FLIPI and FLIPI 2 there were the patients that required treatment in all the risk groups. Conclusion. The FLIPI and FLIPI 2 effectively identify patients at high risk, thus helping in treatment decision for each single patient.

Author Biography

Olivera Simonović, Clinic for hematology and clinical immunology, Clinical Center Niš

specialist of internal medicine, subspecialist in hemathology

References

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89(11): 3909−18.

Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2011; 22(Suppl 6): 59−63.

Agarwal AM, Agarwal N, Glenn MJ, Lim MS. Blastic Transformation of Low-Grade Follicular Lymphoma. J Clin Oncol 2007; 25(16): 2326−8.

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Ar-ranz-Saez R. Follicular Lymphoma International Prog-nostic Index. Blood 2004; 104(5): 1258−65.

Sehn LH. Optimal use of prognostic factors in non Hodg-kin lymphoma. Hematology Am Soc Hematol Educ Pro-gram. 2006: 295−302.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 2000; 95(3): 783−9.

Kersten MJ, Jong Dd, Raemaekers JM, Kluin PM, Hagenbeek A. Beyond the International Prognostic Index: New prognostic factors in follicular lymphoma and diffuse large-cell lymphomaA meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J 2004; 5(3): 202−8.

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351(21): 2159−69.

Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105(1): 301−7.

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic in-dex 2: a new prognostic index for follicular lymphoma devel-oped by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27(27): 4555−62.

Anđelić B, Mihaljević B. Prognostic factors in follicular lymphoma. Acta Clin 2010; 10(3): 49−62.

Katzenberger T, Ott G, Klein T, Kalla J, Muller-Hermelinek HK, Ott MM. Cytogenetic alterations affecting bcl6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B cell component. Am J Pathol 2004; 165(2): 481−90.

Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, Papadaki T. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000; 21(6): 298−305.

Gilles AS. Clinical features, prognosis and treatment of follicular lymphoma. ASH Education Book 2007; 216−25.

Coiffier B. First line treatment of follicilar lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Ocol 2005; 3(6): 484−91.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377(9759): 42−51.

Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9(7): 717−20.

Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005; 16(9): 1508−13.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95(3): 783−9.

Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 Suppl 5): 75−88.

Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report on the national LymphoCare study. J Clin Oncol 2009; 27(8): 1202−8.

Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14(4): 1282−90.

Rosenbaum CA. Evolving paradigms in follicular lymphoma: Reevaluating prognostic factors and challenig treatments dogmas. Molec Oncol Rep 2007; 1(2):33-8.